Price Target Analysis Athersys, Inc. (ATHX)

Lester Mason
October 13, 2017

On Thursday, Shares of Athersys, Inc.

According to Athersys, Inc. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. Next Financial Group, Inc expanded its stake by buying 3,000 shares an increase of 3.2% as of 06/30/2017. Out of the analyst recommendations 2 rate Athersys Inc (NASDAQ:ATHX) stock a Buy, 2 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.

This company has been competing with others in the Healthcare space and offers its own combination of interesting factors Athersys, Inc.

The Relative Volume of the company is 4.69 and Average Volume (3 months) is 1.03 million. Athersys has a one year low of $1.02 and a one year high of $2.63. Athersys, Inc. has had 7 insider trades in the last 3 months, including 0 open market buys and 7 sells. They expect $-0.06 earnings per share, up 14.29 % or $0.01 from last year's $-0.07 per share. Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. Prudential Plc owns $12.39 million in Athersys, Inc., which represents roughly 4.97% of the company's market cap and approximately 23.38% of the institutional ownership. During the same quarter in the previous year, the company posted ($0.08) EPS. The company's revenue for the quarter was up 12.4% compared to the same quarter a year ago.

Examining Institutional Ownership at Athersys, Inc. While it's Return on Investment (ROI) value is -133.8%. If you are viewing this story on another site, it was stolen and reposted in violation of USA and global copyright & trademark law. The legal version of this story can be accessed at https://stocknewstimes.com/2017/10/11/athersys-inc-athx-downgraded-to-hold-at-zacks-investment-research.html. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock.


The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. Following the completion of the transaction, the executive vice president now owns 679,416 shares of the company's stock, valued at $1,474,332.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

05/06/2014 - Athersys, Inc. had its "neutral" rating reiterated by analysts at Edison Group. Analysts on average have given a price target of $7.33 to Athersys, Inc. stock.

The measuring performance with long timeframe can help for taking more accurate investment decision that includes quarter, semi-annual and annual performance.

Shares of Apache Corporation (NYSE:APA) traded down -7.39% in the last session while performance was up 42.46% in the last five days. Northern Trust Corp grew its holdings in Athersys by 30.8% in the 2nd quarter. There has been an observed change of -2.22% in the ownership of the shares in the past six months. Geode Capital Management LLC grew its holdings in Athersys by 35.2% in the 1st quarter.

Athersys, Inc., launched on June 7, 2005, is an worldwide biotechnology company that is focused primarily in the field of regenerative medicine. Athersys is developing MultiStem (r), its patented, adult-derived "off the shelf" stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER